Albumin Shields Fetus From Antibody Drugs

Researchers have identified a method to shield fetuses from potentially harmful antibody-based medications by incorporating albumin into these drugs. This breakthrough, published online on August 20, 2026, in the journal Nature, details how the addition of albumin can effectively block the passage of these therapeutic antibodies through the placenta. The placenta, a vital organ that develops in the uterus during pregnancy, provides oxygen and nutrients to the growing baby and removes waste products from the baby's blood. However, it also acts as a barrier that can prevent certain substances, including some medications, from reaching the fetus.

Antibody-based therapies, which have revolutionized the treatment of various diseases including cancer and autoimmune disorders, work by targeting specific molecules in the body. While highly effective for treating the mother, concerns have been raised about their potential impact on fetal development. The transfer of antibodies across the placenta typically increases significantly during the third trimester, which is a critical period for fetal growth and organ development. This transfer can lead to unintended consequences for the newborn, such as immune suppression or other developmental issues.

The new strategy leverages the natural properties of albumin, a protein abundant in blood plasma that plays a crucial role in maintaining osmotic pressure and transporting various molecules. The researchers found that by conjugating albumin to antibody drugs, they could create a larger molecular complex that is less likely to be transported across the placental barrier. This approach aims to maintain the therapeutic benefits of the antibody treatment for the mother while significantly reducing or eliminating fetal exposure.

This development holds considerable promise for pregnant individuals undergoing treatment for serious conditions. It could pave the way for safer therapeutic options, allowing mothers to receive necessary treatments without posing undue risks to their unborn children. Further research and clinical trials will be necessary to fully validate the efficacy and safety of this albumin-shielding technique across a range of antibody-based medications and for various maternal health conditions. The doi for the publication is 10.1038/d41586-026-02553-x.